<DOC>
	<DOCNO>NCT00981006</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy transplantation autologous human cardiac-derived stem cell ( hCSCs ) control release basic fibroblast growth factor ( bFGF ) severe refractory heart failure patient chronic ischemic cardiomyopathy concordance reduce leave ventricular dysfunction ( 15 % ≦LVEF≦35 % ) .</brief_summary>
	<brief_title>AutoLogous Human CArdiac-Derived Stem Cell Treat Ischemic cArdiomyopathy ( ALCADIA )</brief_title>
	<detailed_description>Autologous human stem progenitor cell different lineage subject clinical trial past treat patient ischemic cardiomyopathy . Although human stem progenitor cell transplantation functional benefit recovery experimental myocardial infarction , major barrier limit clinical application death transplant cell poor cardiac differentiation host environment . Using identical technique clonally cell isolation experimental animal , generate human cardiac-derived stem cell ( hCSC ) enrich Es-marker gene mesenchymal feature . hCSCs include cell population accelerate proliferation presence basic fibroblast growth factor ( bFGF ) plastic plate generate human heart tissue endomyocardial biopsy . Giving patient hCSCs investigational procedure approve committee Ministry Health , Labour , Welfare Japan study . hCSCs excellent potential proliferate regenerate cardiomyocyte compare cell , e.g . myoblasts , bone marrow mononuclear cell bone marrow stem cell , already evaluate preliminary experiment repair injured heart muscle . bFGF possess property promote stem cell proliferation , formation sufficient microvascular network create bFGF critical long-term survival transplant donor cell . This first trial use autologous hCSCs treatment refractory heart failure chronic ischemic cardiomyopathy . This trial translational pilot study look safety efficacy use autologous hCSCs control release bFGF use gelatin hydrogel sheet .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<criteria>1 . Clinical diagnosis ischemic cardiomyopathy Ischemic cardiomyopathy old myocardial infarction due coronary artery atherosclerotic disease . 2 . Age : 20 80 year old 3. leave ventricle ( LV ) dysfunction : An ejection fraction ( EF ) ≧15 % , ≦35 % assess echocardiography 4 . Refractory heart failure : American Heart Association ( AHA ) /American College Cardiology ( ACC ) heart failure Stage D 5 . Heart failure symptom : New York Heart Association ( NYHA ) Class III IV 6 . An indication CABG : A myocardial ischemia accord major coronary artery stenosis ( &gt; 75 % ) 7 . Viability infarct area measure cardiac delay hyperenhancement magnetic resonance imaging ( MRI ) Infarct area affect &gt; 2 contiguous LV segment 18segment model The number segment transmural extent hyperenhancement 51 % less one . Ex1 . infarct area without bypass graft . Ex2 . correlation graft number . Ex3 . case multiple myocardial infarction , indication large infarct volume . 8. write informed consent 1 . New onset myocardial infarction unstable angina within 28 day prior study entry 2 . Indication surgical ventricular reconstruction mitral valve repair *1 3 . Contraindication endomyocardial biopsy *2 4 . Evidence malignant disease within 3 year prior study entry 5 . Chronic hemodialysis 6 . Liver Cirrhosis ( ICGR 15 &gt; 30 % ) 7 . Uncontrollable diabetes mellitus ( HbA1c &gt; 8.0 ) 8 . Maximum diameter Aortic aneurysm 5.5 cm . ( include dissect aneurysm ) 9 . Cardiogenic shock 10 . Active infection ( include cytomegalovirus infection ) 11 . Drug alcoholic dependency 12 . Positive HIV antigen 13 . Active bleeding state ( gastric ulcer , cerebral bleeding , etc . ) 14 . Gelatin allergy *3 15 . Chromosomal abnormality 1 indication LV aneurysmectomy ; patient 2 segment dyskinesis area 2 contraindication endomyocardial biopsy cardiogenic shock endstage uncontrollable congestive heart failure without continue infusion catecholamine complete mobitz type atriaventricular block 3 The screening gelatin allergy necessary patient gelatin patch test gelatinimmunoglobulin E .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ischemic cardiomyopathy ( ICM )</keyword>
</DOC>